OBJECTIVE: This study examined progression to type 2 diabetes and compared healthcare utilization and costs among patients with pre-diabetes, with or without comorbid hypertension. RESEARCH DESIGN AND METHODS: This study drew from a large national claims database (2003-2008). Patients were ≥18 years of age with a medical claim or lab value indicating the presence of pre-diabetes. The index date was the first pre-diabetes diagnosis (ICD-9 codes 790.21, 790.22, 790.29) or qualifying lab value of fasting plasma glucose or impaired glucose intolerance. All patients had ≥12-month data pre- and post- index date. Multivariate analysis was conducted to identify risk factors affecting progression to type 2 diabetes, and to estimate the impact of hypertension status and diabetes progression on healthcare utilization and cost. RESULTS: 144,410 patients met study criteria, with an average follow-up of 802 (SD 344) days. Among participants, 30.7% progressed to diabetes, with a mean 288 (SD 340) days from pre-diabetes identification to diabetes diagnosis. Compared with patients who did not progress, the total adjusted medical costs for patients who developed diabetes increased by $1429 in 1 year, $2451 in 2 years, and $3621 in 3 years (p < 0.001). Patients with concomitant hypertension were significantly more likely to progress to type 2 diabetes, and had higher total medical costs compared to patients without hypertension ($476 higher in 1 year, $949 in 2 years, $1378 in 3 years). CONCLUSIONS: Patients with pre-diabetes who progressed to type 2 diabetes had higher healthcare utilization and costs compared with patients who did not. The presence of hypertension substantially increased costs and was associated with higher likelihood of diabetes progression. Blood pressure, lifestyle intervention, body mass index, and other factors cannot be examined due to the limitations of the data. Results may not be generalizable to patients with insurance other than commercial or Medicare.
OBJECTIVE: This study examined progression to type 2 diabetes and compared healthcare utilization and costs among patients with pre-diabetes, with or without comorbid hypertension. RESEARCH DESIGN AND METHODS: This study drew from a large national claims database (2003-2008). Patients were ≥18 years of age with a medical claim or lab value indicating the presence of pre-diabetes. The index date was the first pre-diabetes diagnosis (ICD-9 codes 790.21, 790.22, 790.29) or qualifying lab value of fasting plasma glucose or impaired glucose intolerance. All patients had ≥12-month data pre- and post- index date. Multivariate analysis was conducted to identify risk factors affecting progression to type 2 diabetes, and to estimate the impact of hypertension status and diabetes progression on healthcare utilization and cost. RESULTS: 144,410 patients met study criteria, with an average follow-up of 802 (SD 344) days. Among participants, 30.7% progressed to diabetes, with a mean 288 (SD 340) days from pre-diabetes identification to diabetes diagnosis. Compared with patients who did not progress, the total adjusted medical costs for patients who developed diabetes increased by $1429 in 1 year, $2451 in 2 years, and $3621 in 3 years (p < 0.001). Patients with concomitant hypertension were significantly more likely to progress to type 2 diabetes, and had higher total medical costs compared to patients without hypertension ($476 higher in 1 year, $949 in 2 years, $1378 in 3 years). CONCLUSIONS:Patients with pre-diabetes who progressed to type 2 diabetes had higher healthcare utilization and costs compared with patients who did not. The presence of hypertension substantially increased costs and was associated with higher likelihood of diabetes progression. Blood pressure, lifestyle intervention, body mass index, and other factors cannot be examined due to the limitations of the data. Results may not be generalizable to patients with insurance other than commercial or Medicare.
Authors: Demetria Hubbard; Lisandro D Colantonio; Rikki M Tanner; April P Carson; Swati Sakhuja; Byron C Jaeger; Robert M Carey; Laura P Cohen; Daichi Shimbo; Mark Butler; Alain G Bertoni; Aisha T Langford; John N Booth; Jolaade Kalinowski; Paul Muntner Journal: Diabetes Care Date: 2019-10-07 Impact factor: 19.112
Authors: Tiffany A Radcliff; Murray J Côté; Melanie D Whittington; Michael J Daniels; Linda B Bobroff; David M Janicke; Michael G Perri Journal: J Acad Nutr Diet Date: 2019-12-30 Impact factor: 4.910
Authors: Natalia Drobek; Paweł Sowa; Piotr Jankowski; Maciej Haberka; Zbigniew Gąsior; Dariusz Kosior; Danuta Czarnecka; Andrzej Pająk; Karolina Szostak-Janiak; Agnieszka Krzykwa; Małgorzata Setny; Paweł Kozieł; Marlena Paniczko; Jacek Jamiołkowski; Irina Kowalska; Karol Kamiński Journal: J Clin Med Date: 2021-05-05 Impact factor: 4.241